Boehringer snags FDA nod on inhaled COPD drug; Grad student develops genetic cancer-drug delivery system;

> An FDA panel gave the go-ahead for Boehringer Ingelheim's once-daily, inhaled COPD drug olodaterol for the treatment of chronic lung disease. Story

> A Virginia Tech graduate student is developing a DNA- and RNA-based drug delivery system that targets genetic diseases and cancer. Release

> Generex Biotechnology of Canada has submitted 12-week Phase III trial results for its oral insulin Generex Oral-lyn to the Indian government for approval. Item

> Researchers in China have found that microparticles with incorporated proteins can be used as a carrier that allows for sustained drug release. Abstract

> Echo Therapeutics ($ECTE) looks to gain approval of its Symphony needle-free transdermal glucose-monitoring system after presenting positive clinical trial results. Release

> Gilead Sciences has initiated a Phase III clinical study of a once-daily, single-tablet regimen to treat HIV. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.